News

Yahoo Finance7y
Sandoz announces US FDA approval and launch of Glatopa® 40 mg/mL three times-a-week generic option for relapsing forms of multiple sclerosis - Yahoo Finance
Holzkirchen, February 13, 2018 - Sandoz, a Novartis division, today announced the US FDA approval and launch of Glatopa ® (glatiramer acetate injection) 40 mg/mL. Glatopa (glatiramer acetate ...
Business Insider7y
Sandoz announces US FDA approval and launch of Glatopa® 40 mg/mL three times-a-week generic option for relapsing forms of multiple sclerosis - Markets Insider
HOLZKIRCHEN, Germany, Feb. 13, 2018 /PRNewswire/ -- Sandoz, a Novartis division, today announced the US FDA approval and launch of Glatopa ® (glatiramer acetate injection) 40 mg/mL. Glatopa ...
Finanznachrichten7y
Novartis International AG: Sandoz announces US FDA approval and launch of Glatopa 40 mg/mL three times-a-week generic option for relapsing forms of ... - FinanzNachrichten.de
Novartis International AG / Sandoz announces US FDA approval and launch of Glatopa 40 mg/mL three times-a-week generic option for relapsing forms of multiple sclerosis . Processed and transmitted ...